drugset / Trial / NCT04331704
ANCHORS Alcohol & Sexual Health Study: UH3 Project
Phase 4
Recruiting
88 enrolled
University of Florida
National Institute on Alcohol Abuse and Alcoholism (NIAAA) · collab
RandomizedParallel-groupOpen-labelPrevention
Summary
80 young adult men will complete an initial survey and receive 1 of 2 types of alcohol and sexual health education and information to encourage prevention of alcohol-related problems, HIV and other sexually transmitted infections (STIs). Participants will then take pre-exposure prophylaxis (PrEP) for HIV prevention and complete a daily 5-minute, telephone-based interactive voice response (IVR) assessment of alcohol/substance use, sexual behavior and PrEP taking for 30 days. Medication will all be active PrEP. There is no placebo control in this study. Follow-up will occur after 30-days and 6-months later.
Timeline
- Start
- 2021-01-12
- Primary completion
- 2025-12-31
- Completion
- 2026-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Background | Tenofovir disoproxil fumarate | Small molecule | 245 mg | — |
| Background | emtricitabine | Other / unclassified | 200 mg | — |